Core-Shell Nanostars for Multimodal Therapy and Imaging by Li, Mengyuan et al.
Core-Shell Nanostars for
Multimodal Therapy and Imaging
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Li, Mengyuan, Lele Li, Changyou Zhan, and Daniel S. Kohane. 2016.
“Core-Shell Nanostars for Multimodal Therapy and Imaging.”
Theranostics 6 (13): 2306-2313. doi:10.7150/thno.15843. http://
dx.doi.org/10.7150/thno.15843.
Published Version doi:10.7150/thno.15843
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29626086
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Theranostics 2016, Vol. 6, Issue 13 
 
 
http://www.thno.org 
2306 
Theranostics 
2016; 6(13): 2306-2313. doi: 10.7150/thno.15843 
Research Paper 
Core–Shell Nanostars for Multimodal Therapy and 
Imaging 
Mengyuan Li, Lele Li, Changyou Zhan, Daniel S. Kohane  
Laboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Division of Critical Care Medicine, Children's Hospital Boston, Harvard Medical 
School, Boston, MA, 02115. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139. Koch Institute for Integrative 
Cancer Research, Massachusetts Institute of Technology, Cambridge MA 02139, USA.  
 Corresponding author: daniel.kohane@childrens.harvard.edu. 
© Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See 
http://ivyspring.com/terms for terms and conditions. 
Received: 2016.04.13; Accepted: 2016.06.16; Published: 2016.10.01 
Abstract 
The coupling of diagnostic capability and effective therapy in a single multifunctional nanomedicine 
is desirable but remains challenging. Here, we developed multifunctional nanoparticles consisting 
of a gold nanostar (AuNS) core with a shell of metal-drug coordination polymer (CP). The AuNS 
core enabled plasmonic photothermal effect and two-photon photoluminescence (TPL), while the 
CP shell of gadolinium and gemcitabine monophosphate allowed chemotherapy and MRI imaging. 
The AuNS@CP nanoparticles exhibited a strong T1 contrast signal and could monitor the 
localization of nanoparticles in vivo through noninvasive MR imaging, while intravital TPL imaging 
could be used to study nanoparticle behavior in tumors at the microscopic level. The combination 
of photothermal therapy and chemotherapy inhibited tumor growth in vivo. 
Key words: gold nanostar, imaging 
Introduction 
Nanoparticles have been used to deliver a wide 
range of therapeutics for cancer treatment. A 
presumed cornerstone of such treatment is the 
tendency of nanoparticles to accumulate in tumors 
due to their leakier vasculature and impaired 
lymphatics, a phenomenon termed enhanced 
permeability and retention (EPR) [1-3]. However, the 
EPR effect is variable from patient to patient, which 
may affect individual therapeutic effectiveness [4]. 
Consequently, there has been interest in integrating 
imaging and therapy in a single theranostic 
nanoplatform to monitor its accumulation and 
efficacy noninvasively, allowing adjustment of a 
regimen to the patient’s specific responses to 
treatment [5-10].  
Gold nanoparticles (AuNPs), such as nanorods, 
nanocages, and nanostars can absorb near-infrared 
(NIR) light and transduce photon energy into heat for 
the thermal ablation of tumors because of surface 
plasmon resonance (SPR) [11-21]. Since NIR light can 
penetrate releatively deeply into tissue without 
causing damage to healthy tissues, such photothermal 
therapy (PTT) is noninvasive and highly localized, 
with minimal systemic toxicity [11-18]. However, PTT 
alone may be unsuccessful in eradicating cancer cells 
completely because of uneven heat distribution and 
attenuation of the light intensity as it travels deeper 
into tissue [14-16]. The light-to-heat conversion 
efficiency of AuNPs may also be changed by 
internalization in cancer cells [19]. The combination of 
PTT with chemotherapy within a single 
multifunctional nanoconstruct has been proposed to 
overcome these limitations [16]. However, most 
anticancer drugs cannot be absorbed onto naked 
AuNPs surfaces due to their weak interaction with Au 
[16]. The strategies reported for drug confinement on 
or around AuNPs often require complex surface 
coatings of AuNPs (e.g., mesoporous silica, polymer) 
through multiple steps [22, 23]. A simple and efficient 
strategy for the integration of imaging and 
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therapeutic agents in a single AuNP is desirable for 
combined therapy (PTT + chemotherapy) to improve 
local therapeutic efficacy, and for imaging to monitor 
the delivery and distribution of nanoparticles [16]. 
Here we report a strategy to coat the AuNP 
surface with a metal-drug coordination polymer (CPs) 
(Fig. 1). CPs, including metal-organic frameworks 
(MOFs), are a new class of hybrid materials composed 
of metal ions and organic ligands linked by 
coordination bonds. [24-27] At the nanoscale, CPs are 
promising materials for vehicles to deliver imaging 
agents and therapeutics, due to their compositional 
and structural tunability, high capacity for drug 
loading, metal sites accessible for binding by 
functional groups on drugs, and ease of surface 
functionalization. [27-31] We report the synthesis of 
core-shell nanocomposites consisting of a gold 
nanostar (AuNS) as the core and a shell of metal-drug 
CP (Gd(III) and gemcitabine phosphate). AuNS with 
multiple branches were chosen here because of their 
easy synthesis without cytotoxic surfactants and the 
potential for high drug loading due to their high 
surface-to-volume ratio [18-21]. Furthermore, the 
plasmon resonance spectra of AuNS can be precisely 
tuned by adjusting their length or number of spikes 
[19]. This system (AuNS@CP) was designed to 
combine photothermal therapy and chemotherapy 
with magnetic resonance (MR) for clinical imaging, as 
well as two-photon luminescence (TPL) imaging to 
enable research on nanoparticle behavior in vivo. We 
applied the AuNS@CP for imaging and cancer 
therapy in a breast cancer xenograft model using the 
4T1 cell line, which is sensitive to gemcitabine [32]. 
Results and Discussion 
Preparation and Characterization of 
AuNS@CP 
The CP shell was composed of the anti-cancer 
drug gemcitabine-5’-monophosphate (GMP, see Fig. 
S1 for the structure) and Gd(III), a coordination 
complex we have reported recently [33]. Gd(III) was 
used because of its coordination flexibility and its 
function as an MRI contrast agent [34]. The core-shell 
AuNS@CP nanostructures were synthesized by a 
two-step method. First, AuNSs (Fig. 2A, B) with a 
mean diameter of 46 nm (by dynamic light scattering, 
DLS, Fig. S2) were synthesized by the reduction of an 
Au (III) salt precursor in HEPES buffer [35]. To ensure 
that the CPs formed a coating on the AuNS (rather 
than forming particles by self-nucleation) [31], the 
particles were first incubated with GMP to allow its 
absorption by coordination interaction between the 
cytosine moiety of GMP and the gold surface [30,31]. 
Then the GMP-coated AuNS were mixed in an 
aqueous solution of GdNO3·3H2O to promote the 
growth of GMP/Gd CP on the surface of the AuNS. 
The particle surface was PEGylated with 
methoxy-PEG bearing two phosphate groups at one 
terminus (PEG-DiP, see Fig. S1 for the structure) that 
could coordinate with Gd(III). The PEGylation of 
nanoparticles was confirmed by Fourier transform 
infrared (FTIR) spectroscopy (Fig. S3), which showed 
the C–O–C stretching vibrations band at 1095 cm−1 
and C–H bending vibrations band at 1336 cm−1, which 
are characteristic of PEG [33, 38].  
 
 
Figure 1. Schematic illustration of the core-shell AuNS@CP nanostructure. 
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Figure 2. Characterization of core-shell AuNS@CP nanostructures. (A-D) TEM images of (A,B) AuNS and (C,D) AuNS@CP (space between black and white lines 
in D indicates CP layer). Scale bar: 50 nm. (E) HAADF-STEM image of AuNS@CP and corresponding EDX elemental maps. (F) UV−vis−NIR absorbance spectra of 
AuNS and AuNS@CP nanoparticles. (G) Effect of irradiance and duration of irradiation (808 nm continuous wave NIR laser) on the temperature of a solution of 
AuNS@CP nanoparticles. Data are means ± SD (N = 4). 
 
The particles had a well-defined core–shell 
structure. The shell thickness could be modified from 
1.8±0.8 to 7.2±3.1 by increasing the mass ratio of GMP 
and GdNO3·3H2O from 1.5:0.6 to 4:1.6, while the mass 
ratios of AuNS and PEG-DiP were kept constant (3:2) 
(Fig. S4). For downstream experiments we used 
particles with shell thicknesses of 5.1 ± 1.8 nm, 
because they allowed the best balance of drug loading 
without aggregation during synthesis. Elemental 
analysis by energy-dispersive X-ray spectroscopy 
(EDX) confirmed the presence of gold (from AuNS), 
fluorine and phosphorus (from GMP), and Gd in the 
particles (Fig. S5). The composition of the core–shell 
nanostructure was confirmed by the EDX elemental 
mapping images obtained from high angle annular 
dark field (HAADF) scanning transmission electron 
microscopy (STEM) (Fig. 2E), which showed the 
presence of the elements Au, Gd, and P (in GMP) in 
the nanostructures. AuNS@CP remained 
monodisperse without obvious aggregation for 24 h in 
human serum buffer (human serum : saline = 1:1, v/v, 
pH 7.4) (Fig. S6; compare to Fig. 2c). UV−vis 
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spectroscopy of as-synthesized AuNS showed 
maximal absorption at 760 nm (Fig. 2F). A red shift to 
805 nm occurred upon formation of the core-shell 
structure.  
The proportions of Au, GMP and Gd(III) in the 
AuNS@CP were 36.8 wt%, 31.5 wt%, and 13.2 wt%, 
respectively, as determined by HPLC and inductively 
coupled plasma mass spectrometry (ICP-MS) (see SI 
for method of calculation). The loading efficiencies of 
GMP and Gd (III) were 85.7% and 90.0%, respectively. 
GMP release studies were performed by immersing a 
dialysis tube filled with 1.0 mL of AuNS@CP (2.5 mM 
Au in saline) into 13.5 mL of saline. At predetermined 
time intervals, 1 mL of the external saline was 
removed (and replaced) and the amount of released 
GMP was analyzed by HPLC. Approximately 49% of 
GMP was released from AuNS@CP in 24 h (Fig. S7).  
The photothermal capability of AuNS@CP (0.5 
mM Au in saline) was investigated by irradiating 
them with an 808 nm continuous wave NIR laser (Fig. 
2G). The bulk temperature of the aqueous solution 
was measured with an infrared thermal camera. 
Irradiation caused the temperature of the AuNS@CP 
solution to increase rapidly during the first 2-4 min 
and plateau within 5 min. The plateau temperature 
increased from 31 to 57 °C as the irradiance increased 
from 42 to 205 mW/cm2. The temperature increase 
was also dependent on the AuNS@CP concentration 
(Figure S8). The plateau temperature increased from 
33 to 56 °C as the Au concentration increased from 
0.0625 to 0.25 mM with light irradiation (0.5 W/cm2). 
The temperature change in irradiated saline without 
AuNS@CP was negligible. 
MR Imaging with AuNS@CP 
The T1-weighted MRI signals of tubes containing 
a range of concentrations of aqueous AuNS@CP were 
measured with a 7T MRI scanner. T1-weighted MR 
images (Fig. 3A, inset) showed that the T1-weighted 
MRI signal intensity increased with increasing 
concentration of AuNS@CP. The molar relaxivity (r1) 
of AuNS@CP, an important parameter that 
determines the efficiency of a MRI contrast agent, was 
determined to be 10.6 mM−1·s−1 by calculating the 
slope of the line relating the Gd(III) concentration to 
the longitudinal relaxation rate (1/T1) of water 
protons (Fig. 3A). To examine the performance of 
AuNS@CP as MRI contrast agents in vivo, nude mice 
bearing ~200 mm3 subcutaneous 4T1 breast cancer cell 
tumors were administered intravenous AuNS@CP 
(0.05 mmol/kg Gd(III)). T1-weighted MR images were 
acquired before injection and at predetermined time 
points afterwards. Enhancement of T1-weighted MR 
signal intensity in the tumor was noted after injection 
compared with pre-injection values: 1.29-fold at 1 h, 
1.39-fold at 2 h, 1.43-fold at 6 h and the enhancement 
remained at 1.24-fold 24 h post-injection (Fig. 3B, C). 
This in vivo MR imaging efficacy and prolonged MRI 
contrast enhancement of the tumor are comparable 
with those of other Gd-based NPs reported recently 
[38, 39].  
 
Figure 3. MR imaging of AuNS@CP in vitro and in vivo. (A) Plot of longitudinal relaxation rate (1/T1) as a function of Gd(III)-concentration in AuNS@CP 
nanoparticles. The slope indicates the molar relaxivity (r1). Data are means ± SD (N=4). Inset: Color-coded T1-weighted MR images of tubes containing AuNS@CP 
nanoparticles at different Gd(III) concentrations, from which the data in the graph were derived. (B) In vivo T1-weighted MR images (color-coded by intensity) 
acquired before and at different time points after i.v. injection of AuNS@CP nanoparticles in 4T1 tumor-bearing mice. Tumors are indicated by white dashed circles. 
(C) Change in the MRI signal intensity of tumor sites after injection of AuNS@CP nanoparticles. Data are means ± SD (N=4) of the quantification of the data in panel 
(B). 
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Figure 4. Representative TPL intravital microscopic images of AuNS@CP nanoparticles in orthotopic 4T1 tumors after i.v. administration of AuNS@CP 
nanoparticles. Green: AuNS@CP, red: Texas Red-dextran (70 kDa) that demarcates blood vessels, blue: intratumoral collagen matrix, yellow: (in the Merge panel), 
the localization of AuNS@CP in blood vessels. 
 
TPL Imaging of Tumor Microenvironment  
In two-photon luminescence (TPL), two low 
energy photons excite a fluorophore with subsequent 
emission of a fluorescence photon of higher energy. 
[40] TPL is noninvasive and can penetrate deeply in 
tissue because much of the emitted light is in the NIR 
region [40-41]. Due to its high resolution, TPL can be a 
useful research tool for imaging and tracking at the 
microscopic level [40-43] (MRI, CT, and PET have 
lower resolution and are often used for whole body 
imaging). In general, gold nanostructures, such as 
AuNS, can provide stronger TPL signals than organic 
fluorophores [42, 43]. We used real-time intravital 
TPL imaging to probe the distribution of AuNS@CP 
in the tumor microenvironment. 
Nude mice bearing ~200 mm3 subcutaneous 4T1 
breast cancer tumors were injected intravenously with 
AuNS@CP (250 nmol Au/kg). Texas Red-dextran 
(molecular weight 70 kDa) was also injected to 
highlight the vasculature [44]. Immediately following 
injection of Texas Red-dextran, the mice were 
anesthetized and the tumor was exposed by a skin 
incision. The tumor was then immobilized on the 
microscope stage for TPL imaging (with NIR 
excitation of 810 nm), while continuity with the body 
vasculature was maintained. [45] Intravital 
multiphoton microscopy imaging of the tumor (Fig. 4) 
revealed that the AuNS@CP reached the tumor 
microvasculature by 10 min after intravenous 
injection. By 1 hour postinjection, extravasated 
photoluminescence (indicating AuNS@CP) was 
observed, and was still present 6 hours after injection. 
Tumor uptake of the NPs was further confirmed by 
3D reconstruction of the TPL imaging data of the 
tumor (Fig. S9), showing that the AuNS@CP 
nanoparticles were mainly distributed outside the 
blood vessels 6 hours after injection.  
Combined Photothermal-chemotherapy  
The photothermal and chemotherapeutic effects 
of the AuNS@CP were evaluated in vitro and in vivo 
with 4T1 breast cancer cells. In vitro, AuNS@CP and 
free GMP exhibited similar time- and 
concentration-dependent cytotoxicity at equivalent 
GMP concentrations over 48 hours (Fig. S10). AuNS 
alone showed little cytotoxicity at a wide range of 
concentrations that are comparable to concentrations 
one might expect in vivo (Fig. S11) [11, 12]. Irradiation 
decreased the viability of 4T1 cancer cells incubated 
with AuNS (Au dose: 11.7 µg/mL) (Fig. 5). Irradiation 
of cells incubated with AuNS@CP (GMP: 10.0 µg/mL) 
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containing the same concentration of gold further 
reduced survival to 3%. Similar degrees of cell killing 
could also be achieved by irradiating cells incubated 
with a higher concentration of AuNS alone (Au: 23.4 
µg/mL; Fig. S12), demonstrating that enhanced 
cytotoxicity could be realized with lower doses of 
AuNS@CP nanoparticle by the addition of 
chemotherapy. Irradiation itself had no effect on cell 
survival, alone or incubated with equivalent 
concentrations of GMP (Fig. 5). We also tested cell 
viability as a function of AuNS@CP concentration 
with and without irradiation (0.5 W/cm2) (Figure 
S13). AuNS@CP could produce significant 
photothermal ablation (beyond that provided by the 
particles alone) at Au concentrations higher than 2.3 
μg/mL (GMP: 2.0 μg/mL, 5 μM). Maximal killing 
(96% of cells were killed) by irradiating particles was 
achieved at a Au concentration of 7.05 μg/mL (GMP: 
6.0 μg/mL, 15 μM). 
The effectiveness of AuNS@CP was investigated 
in vivo in female 4T1 breast tumor-bearing mice. 
When tumors reached about 50 mm3, mice were given 
an intravenous injection of 200 µL of one of the 
following: saline, GMP (10.3 mg GMP/kg), AuNS 
(12.0 mg Au/kg), a mixture of free GMP and AuNS 
(termed AuNS + GMP; 10.3 mg GMP/kg separate 
from 12.0 mg Au/kg), or AuNS@CP (with 10.3 mg 
GMP/kg bound to 12.0 mg Au/kg). One group 
received PEGylated AuNS to control for the effect of 
irradiation of gold alone; their absorbance peak at 
804nm (Fig S14) shows their absorptive properties 
were similar to those of AuNS@CP (Fig. 2F). In the 
laser-treated groups, the tumor site was irradiated 
with a NIR laser (808 nm, 0.5 W/cm2) for 3 minutes, 6 
hours after intravenous injection. In the AuNS@CP + 
laser group, the temperature of the tumor area, 
recorded by an infrared thermal camera (Fig. 6A, B), 
reached 53 ºC after 3 min of irradiation, which is 
sufficient to damage cancer cells irreversibly [39]. The 
same region reached 39 ºC in irradiated saline-treated 
animals (Fig. 6A, B).  
Mice treated with saline exhibited rapid tumor 
growth (Fig. 6C), with a mean tumor volume of 1145 
mm3 on day 15. There was no statistically significant 
difference in final tumor size between saline and 
saline + laser treated groups (p > 0.1), indicating that 
laser irradiation alone had no effect on tumor growth. 
Mice treated with free drug showed a slightly delay in 
tumor growth, with a median tumor volume of 876 
mm3 on day 15 (p = 0.008 vs saline-treated animals). 
Mice treated with AuNS@CP nanoparticles showed 
more tumor inhibition than those treated with free 
GMP (p =0.02), which is consistent with EPR of 
drug-laden nanoparticles. [22, 23, 33] Tumor growth 
in the AuNS + laser and AuNS + GMP + laser groups 
were delayed compared to the saline + laser group 
(with a median tumor volume of 653 mm3 (p =0.02) 
and 447 mm3 (p = 0.02) at day 15, respectively). In the 
AuNS@CP + laser treated group, tumor growth was 
the slowest, with a median tumor volume of 138 mm3 
on day 15 (p = 0.03 vs AuNS@CP). These findings 
suggest that the combination of photothermal therapy 
and chemotherapy provided by AuNS@CP was more 
effective than either modality alone. On histologic 
analysis of hematoxylin-eosin stained sections of 
tumors, the cell density was much lower in the 
AuNS@CP + laser group than in the saline + laser 
group and AuNS@CP group (Fig. 5d, Fig S15), 
indicating that the combination of photothermal 
therapy and chemotherapy was more effective than 
chemotherapy alone. 
 
 
 
Figure 5. Cytotoxicity of AuNS, GMP, and AuNS@CP to 4T1 cells without or with irradiation. 4T1 cells were incubated with or without (no treatment) AuNS, 
GMP, or AuNS@CP (with an equivalent GMP concentration of 10 µg/mL and Au concentration of 11.7 µg/mL) then irradiated with a 808 nm laser (0, 0.25, or 0.5 
W/cm2) for 3 min, 6 h after exposure to treatment groups. After 24 h, cell viability was quantitated by the MTS assay. Data are means ± SD; N = 4. 
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Figure 6. In vivo antitumor activity of AuNS@CP. (A) IR thermal images of 4T1 tumor-bearing mice irradiated (0.5 W/cm2, 3 min) 6 hours after intravenous 
administration of AuNS@CP nanoparticles or saline. (B) Time course of tumor temperature monitored by IR thermal camera during laser irradiation (0.5 W/cm2, 3 
min) as in panel A, 6 hours after intravenous injection with AuNS@CP or saline. (C) Effect of various treatment groups on tumor volume. Data are means ± SD 
ranges; N = 5. *P < 0.05, **P < 0.01. (D) Representative hematoxylin and eosin stained tumor sections collected from mice 3 days after treatment. Scale bar: 100 µm. 
 
The treatments appeared to have no detectable 
systemic toxicity. There was no change in average 
body weight in any of the experimental groups (Fig. 
S16). Histologic analysis of H&E stained sections of 
various organs collected from the AuNS@CP + laser 
group on day 15, the end of the experiment, did not 
show signs of organ damage or inflammatory lesions 
(Fig. S17).  
Conclusion 
Development of single-particle multifunctional 
platforms for theranostics remains a challenge. We 
have demonstrated a simple strategy for the 
integration of multiple therapeutic and imaging 
functionalities in AuNPs. The gold core of the 
AuNS@CP provided plasmonic photothermal effect 
and TPL, while the CP shell provided drug delivery 
and MR imaging, enabling multimodal imaging and 
combined photothermal and chemotherapy. MRI and 
TPL imaging could be used to monitor the in vivo 
distribution of AuNS@CP at the whole body and 
microscopic levels, respectively.  
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